World ADC London 2024 | Hanson Wade | 11 March 2024 | ExCeL London, Royal Victoria Dock, 1 Western Gateway, London E16 1XL, UK

Antibody-drug conjugates are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. Notable achievements include the ground-shaking triumph of ENHERTU, eye-popping investments like Pfizer's monumental $43 billion acquisition of Seagen, and the FDA’s greenlight for ELAHERE. These milestones have transformed the ADC landscape, driving increased interest and investment in the field, which now has a preclinical and clinical arena dynamically evolving.

This will be the first opportunity in the new year to explore these monumental wins, reflect on ongoing challenges, and collaborate on innovative strategies to supercharge all stages of ADC development.

2024 Speakers

Benedicte Recolin
Associate Director - Safety Sciences, AstraZeneca

Dhiraj Gambhire
Executive Director - Global Clinical Lead, Enhertu, Breast & Medical, Daiichi Sankyo

Gerold Meindhardt
Vice President, Asset & Portfolio Management, Daiichi Sankyo

Ian Andrews
Senior Manager, Strategic External Development, GlaxoSmithKline

Lolke De Haan
Vice President - Toxicology, ADC Therapeutics

Martha Neagu
Medical Director, Oncology Early Development, AbbVie

Michael Method
Executive Medical Director, Immunogen

See Phan
Vice President, Clinical Research Oncology, Gilead

2024 Partners

LEAD PARTNER:
• XDC

SENIOR PARTNERS:
• BSP Pharmaceuticals
• Merck
• AJ Ajinomoto
• BioPharma Services
• Glykos

PARTNERS:
• Abzena
• Axplora
• Beacon
• Biocytogen
• Carbogen Amcis
• Catalent Biologics
• Cytiva
• Heraeus
• KBI Biopharma
• Lonza
• Nona Biosciences
• Olon Sustainable Technologies Delivering Science
• Oxford BioTherapeutics
• Piramal Pharma Solutions
• Proveo
• Skymab Biotherapeutics
• Sterling
• Veraxa